The US KOL starts mild patients on methotrexate or apremilast, uses Humira biosimilars as the go-to TNF inhibitor, and tailors later choices to domains and comorbidities like obesity and IBD. The KOL values Bimzelx in TNF inadequate responders, uses Rinvoq exclusively among JAKs, and is lukewarm on deucravacitinib given its middling efficacy. The interview closes with emerging options, including icotrokinra's daily fasting tradeoffs, sonelokimab's unclear differentiation versus Bimzelx, and future T-cell-targeted therapies. 

This interview was conducted on April 27, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.